Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy

Xiaorong Dong

Status and phase: Unknown; Phase 2; Phase 1

Conditions: Chemotherapy; Gut Microbiota; Pembrolizumab; NSCLC

Treatments: Drug: Pembrolizumab Combined With Chemotherapy

Study type: Interventional

Funder types: Other

Identifiers

NCT04333004

1

Details and patient eligibility

About

Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy

Enrollment: 40 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• non-small cell lung cancer patients with less than brain metastases Patients must have received at least the first-line anti-tumor treatment, and the front-line treatment must include chemotherapy or targeted treatment with a platinum containing combination scheme, but not anti-PD-1 / L1 treatment Patients who have not received intracranial local treatment before

Exclusion criteria

• Patients who toke major surgery within 4 weeks prior to enrollment or had ununited wounds Patients with hemorrhage in intracranial metastasis

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

40 participants in 1 patient group

Pembrolizumab Combined With Chemotherapy

Experimental group

Treatment:

Drug: Pembrolizumab Combined With Chemotherapy